Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222293 · ClinicalTrials.gov registry record
Assessment of AI Program 'DRISTi' as a Screening Tool
A clinical trial of Diabetic Retinopathy (DR), sponsored by Artelus AI.
- Recruiting
- Registry status
- 900
- Enrollment target
- 2
- Study locations
NCT07222293 is a study of Diabetic Retinopathy (DR) that is actively recruiting participants, run by Artelus AI. The registered enrollment target is 900 participants, above the 330-participant average among 5 other Diabetic Retinopathy (DR) trials with a reported enrollment target (173% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT07222293, a study of Diabetic Retinopathy (DR), is actively recruiting participants, sponsored by Artelus AI.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 2
- Study locations
Study Summary
A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Fundus Image Grading
Study Locations (2)
North Carolina
- New Century Ophthalmology - Oxford - Oxford
- New Century Ophthalmology - Raleigh - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2025-11-23 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222293
The ClinicalTrials.gov registry entry for NCT07222293 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 330-participant average among 5 other Diabetic Retinopathy (DR) trials with a reported enrollment target (173% higher). The listed sponsor is Artelus AI, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Retinopathy (DR) appearing as the primary indexed condition, and to 1 intervention - of which Fundus Image Grading is the first listed.
NCT07222293 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07222293 about?
NCT07222293 is a clinical study titled "Assessment of AI Program 'DRISTi' as a Screening Tool". A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and ...
What is the current status of trial NCT07222293?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2025-11-23. Estimated completion is 2026-03.
What conditions does trial NCT07222293 study?
This clinical trial studies the following conditions: Diabetic Retinopathy (DR).
What interventions are being tested in trial NCT07222293?
The interventions under investigation include: Fundus Image Grading (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07222293?
This trial is sponsored by Artelus AI, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222293 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy (DR)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE)
RECRUITING · NA
-
Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence
ACTIVE NOT RECRUITING · NA
-
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
ACTIVE NOT RECRUITING · Phase 2
-
A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases
ACTIVE NOT RECRUITING
-
Efficacy and Safety of AEYE Diagnostic Screening (AEYE-DS) Software Device for Detection of Diabetic Retinopathy From Digital Funduscopic Images
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.